全文获取类型
收费全文 | 40065篇 |
免费 | 2525篇 |
国内免费 | 1652篇 |
专业分类
耳鼻咽喉 | 311篇 |
儿科学 | 893篇 |
妇产科学 | 527篇 |
基础医学 | 6226篇 |
口腔科学 | 951篇 |
临床医学 | 3807篇 |
内科学 | 5469篇 |
皮肤病学 | 1273篇 |
神经病学 | 1686篇 |
特种医学 | 848篇 |
外国民族医学 | 7篇 |
外科学 | 2276篇 |
综合类 | 6471篇 |
现状与发展 | 5篇 |
预防医学 | 2625篇 |
眼科学 | 443篇 |
药学 | 7081篇 |
15篇 | |
中国医学 | 1332篇 |
肿瘤学 | 1996篇 |
出版年
2024年 | 54篇 |
2023年 | 439篇 |
2022年 | 756篇 |
2021年 | 1316篇 |
2020年 | 1074篇 |
2019年 | 1028篇 |
2018年 | 986篇 |
2017年 | 1049篇 |
2016年 | 1001篇 |
2015年 | 1113篇 |
2014年 | 2144篇 |
2013年 | 2270篇 |
2012年 | 2156篇 |
2011年 | 2548篇 |
2010年 | 2108篇 |
2009年 | 1950篇 |
2008年 | 2054篇 |
2007年 | 2207篇 |
2006年 | 1887篇 |
2005年 | 1948篇 |
2004年 | 1613篇 |
2003年 | 1528篇 |
2002年 | 1311篇 |
2001年 | 1175篇 |
2000年 | 1067篇 |
1999年 | 1025篇 |
1998年 | 938篇 |
1997年 | 817篇 |
1996年 | 658篇 |
1995年 | 716篇 |
1994年 | 611篇 |
1993年 | 443篇 |
1992年 | 401篇 |
1991年 | 282篇 |
1990年 | 201篇 |
1989年 | 152篇 |
1988年 | 135篇 |
1987年 | 123篇 |
1986年 | 91篇 |
1985年 | 146篇 |
1984年 | 136篇 |
1983年 | 108篇 |
1982年 | 111篇 |
1981年 | 98篇 |
1980年 | 65篇 |
1979年 | 48篇 |
1978年 | 35篇 |
1977年 | 38篇 |
1976年 | 34篇 |
1973年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
1.
2.
3.
4.
5.
6.
Defining con-founders that affect the reliability of diagnostic tests for coronavirus disease 2019 is vital to breaking the chain of infection. The elderly population is a higher risk group for the emerging virus. However, gender seems to exert a critical role in modifying the infection risk among women owing to hormonal changes. The menopause transition is an exceptional period for older women where the protective and immunomodulatory effects of the estrogen hormone are lost. Accordingly, attention should be given to postmenopausal women since they will have an increased risk compared to their pre-menopausal peers. 相似文献
7.
《Orthopaedics and Trauma》2022,36(6):304-310
Congenital vertical talus (CVT) is a rare foot deformity that presents with a rigid flat foot at birth. CVT can present as an isolated abnormality in the newborn, however in at least 50% of cases in association with other conditions. Full neuro-axial imaging is essential to detect any associated neurologic problems. Radiographs of the foot, including forced plantar and dorsiflexion laterals, are diagnostic. Gold standard modern treatment uses the Dobbs method of serial manipulation and casting with minimally-invasive stabilization of the talonavicular joint and Achilles tendon tenotomy. 相似文献
8.
《Clinical microbiology and infection》2022,28(8):1120-1125
ObjectivesOur aim was to evaluate the effect of the updated European Organization for Research and Treatment of Cancer (EORTC) and Mycoses Study Group 2019 definitions for invasive pulmonary aspergillosis (IPA) on patient classification and the related all-cause 12-week mortality.MethodsIn this retrospective cohort study from our tertiary care centre, we reclassified patients with haematological malignancy who underwent bronchoalveolar lavage between 2014 and 2019 for suspected IPA using the novel EORTC 2019 criteria. We performed receiver operating characteristic curve analysis to define the optimal cut-off for positive PCR and galactomannan and present survival analyses and their possible association with these diagnostic criteria through post hoc comparisons with log rank and Cox regression.ResultsFrom 323 episodes of suspected IPA in 282 patients, 73 were reclassified: 31 (42.5%) from possible to probable IPA, 5 (6.8%) from EORTC criteria not met to probable IPA, and 37 (50.7%) from EORTC criteria not met to possible IPA. Probable IPA increased therefore 11.1% (64/323, 19.8% to 100/323, 30.9%), mostly due to positive PCR (31/36, 86.1%). There was no difference in mortality between newly defined possible and probable IPA (log rank p = 0.950). Mortality was higher in probable cases with lower cycle thresholds (Ct values) versus higher Ct values (p = 0.004). Receiver operating characteristic curve analysis showed an optimal Ct value cut-off of 36.8 with a sensitivity of 75% (95% CI 64.9%–85.1%) and a specificity of 61.7% (95% CI 53.5–69.9) for 12-week mortality.DiscussionThe new EORTC criteria led to 11.1% more probable IPA diagnoses, mostly due to Aspergillus PCR. Restricting positive PCR to below a certain threshold might improve the discrimination of the new EORTC IPA categories for mortality. 相似文献
9.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
10.
目的:探讨阿帕替尼单药在标准治疗方案失败晚期结直肠癌(colorectal cancer,CRC)患者中的疗效和安全性。方法:本研究为前瞻性研究设计,用PASS15 软件计算研究所需的样本量,从2017 年7 月到2018 年8 月入组标准方案治疗失败的晚期CRC患者52 例,给予阿帕替尼起始剂量750 mg或500 mg单药治疗;评估患者的客观缓解率(ORR)和疾病控制率(DCR),随访评价患者的无进展生存期(PFS)和总生存期(OS),并记录治疗过程中出现的不良反应。主要研究终点为PFS,次要研究终点为ORR、DCR、OS和安全性。结果:纳入研究的52 例CRC患者中45 例可以评价疗效及安全性,其均为既往接受过至少2 次系统性化疗的晚期CRC患者。疗效:完全缓解0 例、部分缓解5 例、疾病稳定30 例、疾病进展10 例,ORR为11.11%、DCR为77.78%;预后:45 例患者的中位PFS 为3.95 个月(95% CI=3.16~4.74),中位OS为10.3 个月(95% CI=5.70~14.90);3 级以上不良反应:手足综合征6 例(13.33%),高血压5 例(11.11%),蛋白尿5 例(6.67%),转氨酶升高4 例(8.89%),腹泻3 例(6.67%),疲劳2 例(4.44%),出血1例(2.22%)。结论:阿帕替尼单药治疗标准方案失败的晚期CRC患者具有潜在的临床获益,安全性事件总体可控。 相似文献